Pan-Cancer (N=930) | HB-Cancer (N=1151) | Pan-disease (N=4409) | HB-disease (N=21002) | Control (N=5895) | Total (N=33387) | p value | |
---|---|---|---|---|---|---|---|
Gender | < 0.0011 | ||||||
   Female | 439 (47.2%) | 430 (37.4%) | 2043 (46.3%) | 11186 (53.3%) | 1681 (28.5%) | 15779 (47.3%) | |
   Male | 491 (52.8%) | 721 (62.6%) | 2366 (53.7%) | 9816 (46.7%) | 4214 (71.5%) | 17608 (52.7%) | |
Ethnicity | < 0.0011 | ||||||
   White | 519 (66.6%) | 549 (53.7%) | 2370 (57.6%) | 10396 (51.5%) | 3280 (57.7%) | 17114 (53.9%) | |
   South Asian | 79 (10.1%) | 230 (22.5%) | 874 (21.2%) | 5207 (25.8%) | 942 (16.6%) | 7332 (23.1%) | |
   Black | 98 (12.6%) | 121 (11.8%) | 408 (9.9%) | 2046 (10.1%) | 806 (14.2%) | 3479 (10.9%) | |
   Far/South-east Asian | 4 (0.5%) | 24 (2.3%) | 19 (0.5%) | 234 (1.2%) | 31 (0.5%) | 312 (1.0%) | |
   Arab/North African | 0 (0.0%) | 0 (0.0%) | 1 (0.0%) | 15 (0.1%) | 5 (0.1%) | 21 (0.1%) | |
   Asian (Other) | 17 (2.2%) | 46 (4.5%) | 178 (4.3%) | 970 (4.8%) | 234 (4.1%) | 1445 (4.5%) | |
   Mixed | 9 (1.2%) | 8 (0.8%) | 49 (1.2%) | 241 (1.2%) | 78 (1.4%) | 385 (1.2%) | |
   Other | 53 (6.8%) | 45 (4.4%) | 217 (5.3%) | 1065 (5.3%) | 306 (5.4%) | 1686 (5.3%) | |
Diagnosis age (years) | < 0.0012 | ||||||
   Mean (SD) | 66.91 (12.72) | 65.24 (13.22) | 52.90 (18.51) | 53.64 (17.67) | 54.77 (17.59) | 54.51 (17.77) | |
   Median | 67.21 | 66.06 | 51.28 | 52.42 | 54.09 | 53.62 | |
   Q1,Q3 | 58.88, 76.07 | 56.79, 75.15 | 38.36, 67.20 | 39.90, 66.40 | 41.02, 68.00 | 40.66, 67.85 | |
Diagnosis age group | < 0.0011 | ||||||
   18-40 | 27 (2.9%) | 54 (4.7%) | 1318 (29.9%) | 5663 (27.0%) | 1470 (24.9%) | 8532 (25.6%) | |
   41-50 | 66 (7.1%) | 100 (8.7%) | 862 (19.6%) | 4149 (19.8%) | 1097 (18.6%) | 6274 (18.8%) | |
   51-60 | 189 (20.3%) | 266 (23.1%) | 773 (17.5%) | 4186 (19.9%) | 1163 (19.7%) | 6577 (19.7%) | |
   61-70 | 290 (31.2%) | 325 (28.2%) | 574 (13.0%) | 3022 (14.4%) | 961 (16.3%) | 5172 (15.5%) | |
   71-80 | 234 (25.2%) | 273 (23.7%) | 519 (11.8%) | 2311 (11.0%) | 733 (12.4%) | 4070 (12.2%) | |
   >80 | 124 (13.3%) | 133 (11.6%) | 363 (8.2%) | 1671 (8.0%) | 471 (8.0%) | 2762 (8.3%) | |
Mortality | < 0.0011 | ||||||
   Deceased | 754 (81.1%) | 795 (69.1%) | 840 (19.1%) | 3634 (17.3%) | 614 (10.4%) | 6637 (19.9%) | |
   Survived | 176 (18.9%) | 356 (30.9%) | 3569 (80.9%) | 17368 (82.7%) | 5281 (89.6%) | 26750 (80.1%) | |
Survival (months) | < 0.0012 | ||||||
   Mean (SD) | 15.88 (24.91) | 22.37 (29.54) | 49.69 (64.39) | 58.03 (77.33) | 57.50 (71.17) | 54.43 (73.08) | |
   Median | 8.05 | 12.47 | 28.93 | 34.87 | 36.57 | 32.20 | |
   Q1,Q3 | 2.58, 18.18 | 3.52, 29.40 | 9.60, 66.17 | 12.50, 73.46 | 14.57, 71.95 | 11.07, 69.57 |
Pan-Cancer (N=930) | Pan-disease (N=4409) | Total (N=5339) | p value | |
---|---|---|---|---|
Gender | 0.6301 | |||
   Female | 439 (47.2%) | 2043 (46.3%) | 2482 (46.5%) | |
   Male | 491 (52.8%) | 2366 (53.7%) | 2857 (53.5%) | |
Ethnicity | < 0.0011 | |||
   White | 519 (66.6%) | 2370 (57.6%) | 2889 (59.0%) | |
   South Asian | 79 (10.1%) | 874 (21.2%) | 953 (19.5%) | |
   Black | 98 (12.6%) | 408 (9.9%) | 506 (10.3%) | |
   Far/South-east Asian | 4 (0.5%) | 19 (0.5%) | 23 (0.5%) | |
   Arab/North African | 0 (0.0%) | 1 (0.0%) | 1 (0.0%) | |
   Asian (Other) | 17 (2.2%) | 178 (4.3%) | 195 (4.0%) | |
   Mixed | 9 (1.2%) | 49 (1.2%) | 58 (1.2%) | |
   Other | 53 (6.8%) | 217 (5.3%) | 270 (5.5%) | |
Diagnosis age (years) | < 0.0012 | |||
   Mean (SD) | 66.91 (12.72) | 52.90 (18.51) | 55.34 (18.42) | |
   Median | 67.21 | 51.28 | 55.14 | |
   Q1,Q3 | 58.88, 76.07 | 38.36, 67.20 | 40.87, 69.88 | |
Diagnosis age group | < 0.0011 | |||
   18-40 | 27 (2.9%) | 1318 (29.9%) | 1345 (25.2%) | |
   41-50 | 66 (7.1%) | 862 (19.6%) | 928 (17.4%) | |
   51-60 | 189 (20.3%) | 773 (17.5%) | 962 (18.0%) | |
   61-70 | 290 (31.2%) | 574 (13.0%) | 864 (16.2%) | |
   71-80 | 234 (25.2%) | 519 (11.8%) | 753 (14.1%) | |
   >80 | 124 (13.3%) | 363 (8.2%) | 487 (9.1%) | |
Mortality | < 0.0011 | |||
   Deceased | 754 (81.1%) | 840 (19.1%) | 1594 (29.9%) | |
   Survived | 176 (18.9%) | 3569 (80.9%) | 3745 (70.1%) | |
Survival (months) | < 0.0012 | |||
   Mean (SD) | 15.88 (24.91) | 49.69 (64.39) | 43.80 (60.79) | |
   Median | 8.05 | 28.93 | 23.07 | |
   Q1,Q3 | 2.58, 18.18 | 9.60, 66.17 | 6.95, 58.43 |
Pan-Cancer (N=930) | Pan-disease (N=4409) | Total (N=5339) | p value | |
---|---|---|---|---|
Comorbidity | < 0.0011 | |||
   Mean (SD) | 3.27 (2.30) | 2.98 (2.34) | 3.03 (2.34) | |
   Median | 3.00 | 3.00 | 3.00 | |
   Q1,Q3 | 1.00, 5.00 | 1.00, 5.00 | 1.00, 5.00 | |
Diabetes | 353 (38.0%) | 1354 (30.7%) | 1707 (32.0%) | < 0.0012 |
Hypertension | 490 (52.7%) | 2168 (49.2%) | 2658 (49.8%) | 0.0512 |
Cholesterol | 423 (45.5%) | 1831 (41.5%) | 2254 (42.2%) | 0.0262 |
Asthma | 104 (11.2%) | 730 (16.6%) | 834 (15.6%) | < 0.0012 |
COPD | 72 (7.7%) | 315 (7.1%) | 387 (7.2%) | 0.5232 |
TB | 8 (0.9%) | 79 (1.8%) | 87 (1.6%) | 0.0412 |
Kidney | 160 (17.2%) | 844 (19.1%) | 1004 (18.8%) | 0.1692 |
Cardiovascular | 262 (28.2%) | 1091 (24.7%) | 1353 (25.3%) | 0.0292 |
Liver | 99 (10.6%) | 615 (13.9%) | 714 (13.4%) | 0.0072 |
Biliary | 256 (27.5%) | 857 (19.4%) | 1113 (20.8%) | < 0.0012 |
Upper GI | 292 (31.4%) | 1459 (33.1%) | 1751 (32.8%) | 0.3172 |
Lower GI | 109 (11.7%) | 541 (12.3%) | 650 (12.2%) | 0.6412 |
F/H: Cancer | 81 (8.7%) | 1017 (23.1%) | 1098 (20.6%) | < 0.0012 |
F/H: Digestive | 43 (4.6%) | 117 (2.7%) | 160 (3.0%) | 0.0012 |
F/H: Diabetes | 146 (15.7%) | 1176 (26.7%) | 1322 (24.8%) | < 0.0012 |
Pan-Cancer (N=930) | Pan-disease (N=4409) | Total (N=5339) | p value | |
---|---|---|---|---|
Smoker | < 0.0011 | |||
   Not available | 289 (31.1%) | 679 (15.4%) | 968 (18.1%) | |
   Never | 238 (25.6%) | 1419 (32.2%) | 1657 (31.0%) | |
   Past | 236 (25.4%) | 997 (22.6%) | 1233 (23.1%) | |
   Current | 167 (18.0%) | 1314 (29.8%) | 1481 (27.7%) | |
Drinker | < 0.0011 | |||
   Not available | 423 (45.5%) | 1114 (25.3%) | 1537 (28.8%) | |
   Never | 118 (12.7%) | 868 (19.7%) | 986 (18.5%) | |
   Past | 48 (5.2%) | 229 (5.2%) | 277 (5.2%) | |
   Current | 341 (36.7%) | 2198 (49.9%) | 2539 (47.6%) | |
Substance user | < 0.0011 | |||
   Not available | 627 (67.4%) | 2551 (57.9%) | 3178 (59.5%) | |
   Never | 115 (12.4%) | 712 (16.1%) | 827 (15.5%) | |
   Past | 4 (0.4%) | 31 (0.7%) | 35 (0.7%) | |
   Current | 184 (19.8%) | 1115 (25.3%) | 1299 (24.3%) | |
Obese | < 0.0011 | |||
   Not available | 256 (27.5%) | 634 (14.4%) | 890 (16.7%) | |
   Never | 190 (20.4%) | 1106 (25.1%) | 1296 (24.3%) | |
   Past | 337 (36.2%) | 1531 (34.7%) | 1868 (35.0%) | |
   Current | 147 (15.8%) | 1138 (25.8%) | 1285 (24.1%) |
Pan-Cancer (N=540) | Pan-disease (N=3439) | Total (N=3979) | p value | |
---|---|---|---|---|
Gender | 0.1871 | |||
   Female | 265 (49.1%) | 1583 (46.0%) | 1848 (46.4%) | |
   Male | 275 (50.9%) | 1856 (54.0%) | 2131 (53.6%) | |
Ethnicity | < 0.0011 | |||
   White | 324 (60.3%) | 1838 (53.7%) | 2162 (54.6%) | |
   South Asian | 71 (13.2%) | 842 (24.6%) | 913 (23.1%) | |
   Black | 87 (16.2%) | 374 (10.9%) | 461 (11.6%) | |
   Far/South-east Asian | 2 (0.4%) | 17 (0.5%) | 19 (0.5%) | |
   Arab/North African | 0 (0.0%) | 1 (0.0%) | 1 (0.0%) | |
   Asian (Other) | 15 (2.8%) | 162 (4.7%) | 177 (4.5%) | |
   Mixed | 5 (0.9%) | 41 (1.2%) | 46 (1.2%) | |
   Other | 33 (6.1%) | 147 (4.3%) | 180 (4.5%) | |
Diagnosis age (years) | < 0.0012 | |||
   Mean (SD) | 67.15 (13.68) | 52.54 (18.34) | 54.53 (18.46) | |
   Median | 67.01 | 50.69 | 53.64 | |
   Q1,Q3 | 57.95, 77.72 | 38.21, 66.39 | 39.99, 68.71 | |
Diagnosis age group | < 0.0011 | |||
   18-40 | 19 (3.5%) | 1051 (30.6%) | 1070 (26.9%) | |
   41-50 | 41 (7.6%) | 690 (20.1%) | 731 (18.4%) | |
   51-60 | 115 (21.3%) | 610 (17.7%) | 725 (18.2%) | |
   61-70 | 148 (27.4%) | 432 (12.6%) | 580 (14.6%) | |
   71-80 | 124 (23.0%) | 370 (10.8%) | 494 (12.4%) | |
   >80 | 93 (17.2%) | 286 (8.3%) | 379 (9.5%) | |
Mortality | < 0.0011 | |||
   Deceased | 437 (80.9%) | 618 (18.0%) | 1055 (26.5%) | |
   Survived | 103 (19.1%) | 2821 (82.0%) | 2924 (73.5%) | |
Survival (months) | < 0.0012 | |||
   Mean (SD) | 17.83 (29.58) | 57.69 (69.11) | 52.28 (66.58) | |
   Median | 7.93 | 35.47 | 30.17 | |
   Q1,Q3 | 2.58, 18.38 | 15.12, 74.20 | 11.53, 68.25 |
Pan-Cancer (N=540) | Pan-disease (N=3439) | Total (N=3979) | p value | |
---|---|---|---|---|
Comorbidity | < 0.0011 | |||
   Mean (SD) | 4.29 (2.18) | 3.42 (2.35) | 3.54 (2.35) | |
   Median | 4.00 | 3.00 | 3.00 | |
   Q1,Q3 | 3.00, 6.00 | 2.00, 5.00 | 2.00, 5.00 | |
Diabetes | 250 (46.3%) | 1124 (32.7%) | 1374 (34.5%) | < 0.0012 |
Hypertension | 353 (65.4%) | 1866 (54.3%) | 2219 (55.8%) | < 0.0012 |
Cholesterol | 361 (66.9%) | 1692 (49.2%) | 2053 (51.6%) | < 0.0012 |
Asthma | 78 (14.4%) | 644 (18.7%) | 722 (18.1%) | 0.0162 |
COPD | 52 (9.6%) | 259 (7.5%) | 311 (7.8%) | 0.0912 |
TB | 8 (1.5%) | 78 (2.3%) | 86 (2.2%) | 0.2432 |
Kidney | 133 (24.6%) | 727 (21.1%) | 860 (21.6%) | 0.0672 |
Cardiovascular | 192 (35.6%) | 927 (27.0%) | 1119 (28.1%) | < 0.0012 |
Liver | 83 (15.4%) | 560 (16.3%) | 643 (16.2%) | 0.5922 |
Biliary | 186 (34.4%) | 745 (21.7%) | 931 (23.4%) | < 0.0012 |
Upper GI | 248 (45.9%) | 1405 (40.9%) | 1653 (41.5%) | 0.0262 |
Lower GI | 98 (18.1%) | 530 (15.4%) | 628 (15.8%) | 0.1052 |
F/H: Cancer | 81 (15.0%) | 1017 (29.6%) | 1098 (27.6%) | < 0.0012 |
F/H: Digestive | 29 (5.4%) | 108 (3.1%) | 137 (3.4%) | 0.0082 |
F/H: Diabetes | 146 (27.0%) | 1171 (34.1%) | 1317 (33.1%) | 0.0012 |
Pan-Cancer (N=540) | Pan-disease (N=3439) | Total (N=3979) | p value | |
---|---|---|---|---|
Smoker | < 0.0011 | |||
   Not available | 5 (0.9%) | 12 (0.3%) | 17 (0.4%) | |
   Never | 201 (37.2%) | 1312 (38.2%) | 1513 (38.0%) | |
   Past | 203 (37.6%) | 955 (27.8%) | 1158 (29.1%) | |
   Current | 131 (24.3%) | 1160 (33.7%) | 1291 (32.4%) | |
Drinker | < 0.0011 | |||
   Not available | 96 (17.8%) | 449 (13.1%) | 545 (13.7%) | |
   Never | 86 (15.9%) | 779 (22.7%) | 865 (21.7%) | |
   Past | 47 (8.7%) | 227 (6.6%) | 274 (6.9%) | |
   Current | 311 (57.6%) | 1984 (57.7%) | 2295 (57.7%) | |
Substance user | 0.0031 | |||
   Not available | 331 (61.3%) | 1828 (53.2%) | 2159 (54.3%) | |
   Never | 72 (13.3%) | 630 (18.3%) | 702 (17.6%) | |
   Past | 4 (0.7%) | 28 (0.8%) | 32 (0.8%) | |
   Current | 133 (24.6%) | 953 (27.7%) | 1086 (27.3%) | |
Obese | < 0.0011 | |||
   Not available | 7 (1.3%) | 65 (1.9%) | 72 (1.8%) | |
   Never | 117 (21.7%) | 933 (27.1%) | 1050 (26.4%) | |
   Past | 292 (54.1%) | 1420 (41.3%) | 1712 (43.0%) | |
   Current | 124 (23.0%) | 1021 (29.7%) | 1145 (28.8%) |